Medical treatment of juvenile idiopathic arthritis;Evidenz-basierte therapie der juvenilen idiopathischen arthritis

Medizinische Monatsschrift fur Pharmazeuten

Volumn 31, Issue 9, 2008, Pages 326-336

  Horneff, Gerd ^a  

^a Asklepios Klinik Sankt Augustin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AUTOIMMUNE DISEASE; CHRONIC DISEASE; CLINICAL FEATURE; HUMAN; JOINT DEGENERATION; JUVENILE RHEUMATOID ARTHRITIS; PROGNOSIS; REVIEW; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CYCLOOXYGENASE 2 INHIBITORS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-1; INTERLEUKIN-6; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 52449089373     PISSN: 03429601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 1998;25:1991-4.
2. Petty RE, Southwood TR, Manners P, Baum J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis. Second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
3. Cassidy JT, Petty RE. Textbook of Pediatric Rheumatology. 4. Ausgabe. Philadelphia, London, New York: WB Saunders, 2001:214-7.
4. Petty RE. Prognosis in children with rheumatic diseases: justification for consideration of new therapies. Rheumatology 1999;38:739-42.
5. Flato B, Aasland A, Vinje O, Forre O. Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondylarthropathy. J Rheumatol 1998;25:366-75.
6. Minden K, Niewerth M, Listing J, Biedermann T, et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:2392-401.
7. Giannini EH, Ruperto N, Raveli A, Lovell DJ, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
8. Haapasaari J, Wuolijoki E, Ylijoki H. Treatment of juvenile rheumatoid arthritis with diclofenac sodium. Scand J Rheumatol 1983;12:325-30.
9. Giannini EH, Brewer EJ, Miller ML, Gibbas D, et al. Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. J Pediatr 1990;117:645-52.
10. Kvien TK, Hoyeraal HM, Sandstad B. Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthritis. Assessment of tolerance and efficacy in a single-centre 24-week double-blind parallel study. Scand J Rheumatol 1984;13:342-50.
11. Mäkelä AL. Naproxen in the treatment of juvenile rheumatoid arthritis. Metabolism, safety and efficacy. Scand J Rheumatol 1977;6:193-205.
12. Garcia-Morteo O, Maldonado-Cocco JA, Cuttica R, Garay SM. Piroxicam in juvenile rheumatoid arthritis. Eur J Rheumatol Inflamm 1987;8:49-53.
13. Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, et al. and the Pediatric Rheumatology International Trials Organization. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum 2005;52:563-72.
14. Reiff A, Lovell DJ, Adelsberg JV, Kiss MH, et al. Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. J Rheumatol 2006;33:985-95.
15. Young D. FDA advisers endorse celebrex for juvenile rheumatoid arthritis: lack of studies in children raises safety concerns. Am J Health Syst Pharm 2007;64:11-2.
16. Zulian F, Martini G, Gobber D, Plebani M, et al. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology (Oxford) 2004;43:1288-91.
17. Brewer EJ, Giannini EH, Kuzmina N, Alekseev L. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial. N Engl J Med 1986;314:1269-76.
18. Giannini EH, Brewer EJ Jr., Kuzmina N, Shaikov A, et al. Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The USA Pediatric Rheumatology Collaborative Study Group. The USSR Cooperative Children's Study Group. Arthritis Rheum 1990;33:466-76.
19. Ansell BM, Hall MA, Loftus JK, Woo P, et al. A multicentre pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol 1991;9:201-3.
20. Van Rossum MA, Fiselier TJ, Franssen MJ, Zwinderman AH, et al. Sulfasalzin in the treatment of juvenile chronic arthritis. A randomized double-blind placebo-controlled multicenter study. Arthritis Rheum 1998;41:808-16.
21. Burgos-Vargas R, Vazquez-Mellado J, Pacheco-Tena C, Hernandez-Garduno A, et al. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis 2002;61:941-2.
22. Kvien TK, Hoyeraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol 1986;13:118-23.
23. Gianinni EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double blind, placebo-controlled trial. N Engl J Med 1992;326:1043-9.
24. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, et al.; Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201.
25. Woo P, Southwood TR, Prieur AM, Dore CJ, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43:1849-57.
26. Jundt JW, Browne BA, Fiocco GP, Steele AD, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993;20:1845-9.
27. Niehues T, Horneff G, Michels H, Sailer-Höck M, et al. Evidenz-basierter Einsatz von Methotrexat bei Kindern mit rheumatischen Erkrankungen. Konsensusstatement der Arbeitsgemeinschaft Kinder- und Jugendrheumatologie Deutschland (AGKIR) und Arbeitsgemeinschaft Pädiatrische Rheumatologie Österreich. Monatsschr Kinderheilkd 2003;151:881-90.
28. Silverman E, Mouy R, Spiegel L, Jung LK, et al.; Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005;352:1655-66.
29. Cannon GW, Pincus SH, Emkey RD, Denes A, et al. Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1989;32:964-73.
30. Horneff G, Schmeling H, Biedermann T, Foeldvari I, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis (JIA). Ann Rheum Dis 2004;63:1638-44.
31. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
32. Quartier P, Taupin P, Bourdeaut F, Lemelle I, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-101.
33. Heiligenhaus A, Mingels A, Neudorf U, Ganser G. Juvenile idiopathische Arthritis und Uveitis: Screening und antientzündliche Therapie. Klin Monatsbl Augenheilkd 2003;220:738-53.
34. Lovell DJ, Reiff A, Jones OY, Schneider R, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94.
35. Horneff G. Biologika zur Therapie der juvenilen idiopathischen Arthritis - update 2007. Aktuelle Rheumatologie 2007;32:128-35.
36. Horneff G. Einsatz von Biologika bei der juvenilen idiopathischen Arthritis. Konsensus-Statement des 7. Wörlitzer Expertengespräches 2004 für die Arbeitsgemeinschaft Kinder- und Jugendrheumatologie. Z Rheumatol 2006;65:152-6.
37. Horneff G, Ruperto N, Martini A, Carcereri R. Behandlung von Kindern mit juveniler rheumatoider Arthritis (JRA) mit Adalimumab - Studienergebnisse nach 48 Wochen. Z Rheumatol 2006;65:S6.
38. Ruperto N, Lovell DJ, Goodman S, Reiff A, et al. 48 week data from the study of adalimumab in children with juvenile rheumatoid arthritis (JRA). EULAR Amsterdam 21.-24.6.06. Ann Rheum Dis 2006;65 (Suppl 1):56.
39. Lovell DJ, Ruperto N, Cuttica R, et al. Comparison of safety, efficacy and pharmacokinetics for 3 and 6 mg/kg infliximab plus methotrexate therapy in JRA patients. Arthritis Rheum 2005;52:724S.
40. Manger B. Überarbeitete Empfehlungen der Deutschen Gesellschaft für Rheumatologie zur Therapie mit Tumornekrosefaktor-hemmenden Wirkstoffen bei entzündlich rheumatischen Erkrankungen. Kommission Pharmakotherapie der Deutschen Gesellschaft für Rheumatologie Z Rheumatol 2002;61:694-7.
41. Irigoyen P, Olson J, Hom C, Ilowite N. Treatment of systemic onset juvenile idiopathic arthritis with anakinra. Ped Rheum online 2006;4:123-34.
42. Reiff A. The use of anakinra in juvenile arthritis. Curr Rheumatol Rep 2005;6:434-40.
43. Lovell DJ, Gianinni EH, Kimura Y, et al. Prelimonary evidence for bioactivity of IL-1 trap (rilonacept), a long acting il-1 inhibitor, in systemic juvenile idiopathic arthritis (sJIA). Arthritis Rheum 2006;54:S325.
44. Yokota S, Miyamae T, Imagawa T, Iwata N, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005;52:818-25.
45. Yokota S, Imagawa T, Mori M, et al. Rapid improvement of signs and symptoms associated with systemic juvenile idiopathic arthritis (sJIA) by interleukin-6 (IL-6) blockade-results of a tocilizumab sJIA phase III clinical trial. Arthritis Rheum 2006;54:S327.
46. Ruperto N, Lovell DJ, Quartier P, Paz E, et al. Abatacept in children with juvenile idiopathic arthritis; a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-391.
47. Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum 2006;5:1595-601.